Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase II study to evaluate the safety and efficacy of
single-agent AT-101 in patients with relapsed or refractory B-cell malignancies.